Steven John Woodhead

USPTO Granted Patents = 15 (Patent Applications = 4)

CIPO Patents = 2

EPO Patents = 7 (Patent Applications = 7)

Average Co-Inventor Count = 7.7

ph-index = 10

Forward Citations = 216(Granted Patents)

Company Filing History:

13 out of 123

Astex Therapeutics Limited

patents

2 out of 1,177

Takeda Pharmaceutical Company Limited

The Institute of Cancer Research: Royal Cancer Hospital

patents

5. 1 out of 1

Cancer Research Technology Limtied

patent

where one patent can have more than one assignee

Years Active: 2013-2019

Loading Chart...

15 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10519137 - Pyrazolyl quinoxaline kinase inhibitors (2019-12-31),

2. 10052320 - Substituted quinoxalines as FGFR kinase inhibitors (2018-08-21),

3. 10039759 - Quinolines as FGFR kinase modulators (2018-08-07),

4. 9994547 - Heteroarylamide inhibitors of TBK1 (2018-06-12),

5. 9856236 - Substituted quinoxalines as FGFR kinase inhibitors (2018-01-02),

6. 9850228 - Pyrazolyl quinoxaline kinase inhibitors (2017-12-26),

7. 9598424 - Heteroarylamide inhibitors of TBK1 (2017-03-21),

8. 9464071 - Pyrazolyl quinoxaline kinase inhibitors (2016-10-11),

9. 9439896 - Quinolines as FGFR kinase modulators (2016-09-13),

10. 9303029 - Substituted quinoxalines as FGFR kinase inhibitors (2016-04-05),

11. 9290478 - Substituted quinoxalines as FGFR kinase inhibitors (2016-03-22),

12. 8895601 - Pyrazolyl quinoxaline kinase inhibitors (2014-11-25),

13. 8796244 - Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases (2014-08-05),

14. 8685980 - Pyrrolopyrimidine compounds and their uses (2014-04-01),

15. 8497294 - Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases (2013-07-30),

Title: The Innovative Contributions of Steven John Woodhead

Introduction

Steven John Woodhead is a prominent inventor based in San Diego, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of kinase inhibitors. With a total of 15 patents to his name, Woodhead's work has the potential to impact the treatment of various diseases, including cancer.

Latest Patents

Among his latest patents are the "Pyrazolyl quinoxaline kinase inhibitors," which relate to new quinoxaline derivative compounds. This invention includes pharmaceutical compositions comprising these compounds, processes for their preparation, and their use in treating diseases such as cancer. Another notable patent is for "Substituted quinoxalines as FGFR kinase inhibitors," which also involves new quinoxaline derivative compounds and their applications in pharmaceutical compositions for disease treatment.

Career Highlights

Woodhead has worked with notable companies in the pharmaceutical industry, including Astex Therapeutics Limited and Takeda Pharmaceutical Company Limited. His experience in these organizations has allowed him to develop innovative solutions that address critical health challenges.

Collaborations

Some of his coworkers include Valerio Berdini and Gordon Saxty, who have collaborated with him on various projects, contributing to the advancement of pharmaceutical research.

Conclusion

Steven John Woodhead's innovative work in the field of pharmaceuticals, particularly in kinase inhibitors, showcases his dedication to improving healthcare outcomes. His patents and collaborations reflect a commitment to advancing medical science and providing new treatment options for patients.

This text is generated by artificial intelligence and may not be accurate.